BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 27739239)

  • 1. Critical congenital heart defects and abnormal levels of routinely collected first- and second-trimester biomarkers.
    Borelli M; Baer RJ; Chambers CD; Smith TC; Jelliffe-Pawlowski LL
    Am J Med Genet A; 2017 Feb; 173(2):368-374. PubMed ID: 27739239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First trimester combined screening biochemistry in detection of congenital heart defects.
    Alanen J; Korpimaki T; Kouru H; Sairanen M; Leskinen M; Gissler M; Ryynanen M; Nevalainen J
    J Matern Fetal Neonatal Med; 2019 Oct; 32(19):3272-3277. PubMed ID: 29683008
    [No Abstract]   [Full Text] [Related]  

  • 3. Using second trimester ultrasound and maternal serum biomarker data to help detect congenital heart defects in pregnancies with positive triple-marker screening results.
    Jelliffe-Pawlowski LL; Walton-Haynes L; Currier RJ
    Am J Med Genet A; 2008 Oct; 146A(19):2455-67. PubMed ID: 18785270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prenatal screening for fetal aneuploidy in singleton pregnancies.
    Chitayat D; Langlois S; Douglas Wilson R; ;
    J Obstet Gynaecol Can; 2011 Jul; 33(7):736-750. PubMed ID: 21749752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of critical congenital heart defects by nuchal translucency norms.
    Jelliffe-Pawlowski LL; Norton ME; Shaw GM; Baer RJ; Flessel MC; Goldman S; Currier RJ
    Am J Obstet Gynecol; 2015 Apr; 212(4):518.e1-10. PubMed ID: 25448520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of second trimester screen positive pregnancies at increased risk for congenital heart defects.
    Jelliffe-Pawlowski LL; Walton-Haynes L; Currier RJ
    Prenat Diagn; 2009 Jun; 29(6):570-7. PubMed ID: 19266536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maternal first trimester serum levels of free-beta human chorionic gonadotrophin and male genital anomalies.
    Schneuer FJ; Bower C; Holland AJ; Tasevski V; Jamieson SE; Barker A; Lee L; Majzoub JA; Nassar N
    Hum Reprod; 2016 Aug; 31(8):1895-903. PubMed ID: 27496947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First trimester predictors of adverse pregnancy outcomes.
    Brameld KJ; Dickinson JE; O'Leary P; Bower C; Goldblatt J; Hewitt B; Murch A; Stock R
    Aust N Z J Obstet Gynaecol; 2008 Dec; 48(6):529-35. PubMed ID: 19133038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Critical congenital heart disease: contemporary prenatal screening performance and outcomes in a multi-centre perinatology service.
    Cody F; Franklin O; Mc Cay N; Molphy Z; Dicker P; Breathnach FM
    BMC Pregnancy Childbirth; 2024 Feb; 24(1):163. PubMed ID: 38402176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The association of maternal lymphatic markers and critical congenital heart defects in the fetus-A population based case-control study.
    Steurer MA; Norton ME; Baer RJ; Shaw GM; Keating S; Moon-Grady AJ; Chambers CD; Jelliffe-Pawlowski LL
    Am J Med Genet A; 2017 May; 173(5):1231-1236. PubMed ID: 28323386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Evaluation of pregnancy-associated plasma protein A (PAPP-A) and free beta subunit of human chorionic gonadotropin (beta hCG) levels and sonographic assesement of fetal nuchal translucency (NT) in singleton pregnancies between 11 and 14 weeks of gestation--Polish multi-centre research].
    Borowski D; Czuba B; Cnota W; Hincz P; Czekierdowski A; Gajewska J; Jaczyńska R; Ceran A; Włoch A; Wyrwas D; Wiełgoś M; Szymusik I; Szaflik K; Sodowski K
    Ginekol Pol; 2007 May; 78(5):384-7. PubMed ID: 17867331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated first-trimester nuchal translucency increases the risk of congenital heart defects.
    Bahado-Singh RO; Wapner R; Thom E; Zachary J; Platt L; Mahoney MJ; Johnson A; Silver RK; Pergament E; Filkins K; Hogge WA; Wilson RD; Jackson LG;
    Am J Obstet Gynecol; 2005 May; 192(5):1357-61. PubMed ID: 15902108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Uptake of prenatal screening for chromosomal anomalies: impact of test results in a previous pregnancy.
    Spencer K
    Prenat Diagn; 2002 Dec; 22(13):1229-32. PubMed ID: 12478639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperglycosylated-hCG (h-hCG) and Down syndrome screening in the first and second trimesters of pregnancy.
    Palomaki GE; Neveux LM; Haddow JE; Wyatt P
    Prenat Diagn; 2007 Sep; 27(9):808-13. PubMed ID: 17590886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in prenatal screening for Down syndrome: II first trimester testing, integrated testing, and future directions.
    Benn PA
    Clin Chim Acta; 2002 Oct; 324(1-2):1-11. PubMed ID: 12204419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical usefulness of biochemical (free β-hCg, PaPP-a) and ultrasound (nuchal translucency) parameters in prenatal screening of trisomy 21 in the first trimester of pregnancy.
    Ziolkowska K; Dydowicz P; Sobkowski M; Tobola-Wrobel K; Wysocka E; Pietryga M
    Ginekol Pol; 2019; 90(3):161-166. PubMed ID: 30950006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First- and second-trimester screening: detection of aneuploidies other than Down syndrome.
    Breathnach FM; Malone FD; Lambert-Messerlian G; Cuckle HS; Porter TF; Nyberg DA; Comstock CH; Saade GR; Berkowitz RL; Klugman S; Dugoff L; Craigo SD; Timor-Tritsch IE; Carr SR; Wolfe HM; Tripp T; Bianchi DW; D'Alton ME;
    Obstet Gynecol; 2007 Sep; 110(3):651-7. PubMed ID: 17766613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ultrasonographic markers for chromosomal abnormalities in women with negative nuchal translucency and second trimester maternal serum biochemistry.
    Verdin SM; Whitlow BJ; Lazanakis M; Kadir RA; Chatzipapas I; Economides DL
    Ultrasound Obstet Gynecol; 2000 Oct; 16(5):402-6. PubMed ID: 11169322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Obstetrical complications associated with abnormal maternal serum markers analytes.
    Gagnon A; Wilson RD;
    J Obstet Gynaecol Can; 2008 Oct; 30(10):918-932. PubMed ID: 19038077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum free β-human chorionic gonadotropin in the three trimesters of pregnancy: effects of maternal characteristics and medical history.
    Wright D; Papadopoulos S; Silva M; Wright A; Nicolaides KH
    Ultrasound Obstet Gynecol; 2015 Jul; 46(1):51-9. PubMed ID: 25846870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.